MaxCyte (NASDAQ:MXCT) Raised to Hold at Wall Street Zen

MaxCyte (NASDAQ:MXCT) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Sunday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MaxCyte in a research note on Monday, December 29th. One research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $6.00.

MaxCyte Price Performance

Shares of NASDAQ MXCT opened at $0.81 on Friday. MaxCyte has a 12 month low of $0.64 and a 12 month high of $3.33. The company has a 50-day simple moving average of $0.96 and a 200-day simple moving average of $1.35. The company has a market cap of $86.51 million, a PE ratio of -1.84 and a beta of 1.22.

Institutional Trading of MaxCyte

Several large investors have recently added to or reduced their stakes in the stock. Virtu Financial LLC acquired a new stake in MaxCyte during the 4th quarter valued at $67,000. Millennium Management LLC raised its position in shares of MaxCyte by 1,082.6% in the 4th quarter. Millennium Management LLC now owns 1,292,773 shares of the company’s stock valued at $2,004,000 after purchasing an additional 1,183,461 shares in the last quarter. Jain Global LLC acquired a new stake in MaxCyte in the fourth quarter valued at $45,000. Public Employees Retirement System of Ohio bought a new position in shares of MaxCyte during the fourth quarter worth about $103,000. Finally, Graham Capital Management L.P. increased its holdings in MaxCyte by 111.1% in the fourth quarter. Graham Capital Management L.P. now owns 55,736 shares of the company’s stock valued at $86,000 after buying an additional 29,330 shares during the last quarter. 68.81% of the stock is currently owned by institutional investors and hedge funds.

MaxCyte Company Profile

MaxCyte, Inc (NASDAQ: MXCT) is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.